Cartesian Therapeutics, Inc.
NASDAQ:RNACBiotechnology
-$0.41 today
- Market cap
- $192.17M
- Beta
- 0.78
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$5.65
Volume 0.17M
Average 0.26M
RNAC Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
Cartesian Therapeutics, Inc.NASDAQ: RNAC
Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026
Other non-cash items turns positive
Q1 FY2026 other non-cash items was $13.94M, compared with -$1.98M a year earlier. Trailing-twelve-month other non-cash items was $76.06M. Over 3 fiscal years it compounded at +197.2% a year.
Context
- Other non-cash items amounted to 2150.1% of revenue in FY2025, up 2017.7 pp from a year earlier.
- Other non-cash items increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly other non-cash items holds near $13.94M or moves back toward the trailing-twelve-month quarterly average of $19.01M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Non-Cash Items history
USD · from the cash flow
- Latest · FY2025
- 60.14M USD
- Year-over-year change
- +16.7%
- 4-year CAGR
- +130.5%
| Period | Period end | Other Non-Cash Items | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 60.14M | +16.7% |
| FY2024 | 2024-12-31 | 51.52M | -67.6% |
| FY2023 | 2023-12-31 | 159.21M | +6852.4% |
| FY2022 | 2022-12-31 | 2.29M | +7.5% |
| FY2021 | 2021-12-31 | 2.13M | — |
Other Non-Cash Items vs competitors
How RNAC compares with its peers on the latest reported figures
- Peers report in different currencies, so other non-cash items is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1731.8% is the 2nd highest of 9, against a peer median of +36.3%.
- Other non-cash items amounts to 4285.0% of revenue for RNAC, versus a peer median of 6.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | €205.07M EUR | +121.4% | +245.4% | 4574.3% | |
| LTM Mar 2026 | $76.06M USD | +1731.8% | +197.2% | 4285.0% | |
| LTM Mar 2026 | $8.62M USD | +106.6% | +6.9% | 14616.9% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $7.32M USD | +1998.8% | +92.4% | — |
| LTM Mar 2026 | $4.01M USD | — | — | — | |
| LTM Mar 2026 | $2.86M USD | +936.2% | -52.0% | — | |
| LTM Mar 2026 | $969K USD | -33.9% | +16.7% | 3.0% | |
| LTM Mar 2026 | $947K USD | -45.9% | +16.9% | — | |
| LTM Mar 2026 | $915.33K USD | -755.7% | — | 6.3% | |
| LTM Mar 2026 | $229.14K USD | -86.7% | +47.5% | 0.4% | |
| Peer median (excluding RNAC) | — | +36.3% | +16.9% | 6.3% | |
Competitors are the stored peer set for RNAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (25.69M) | 35.38M | (219.71M) | (77.42M) | (130.3M) |
| Depreciation & Amortization | 1.25M | 1.29M | 843K | 1.15M | 2.96M |
| Deferred Income Tax | 2.4M | (21.4M) | (19M) | 287K | (9.19M) |
| Stock-Based Compensation | 7.72M | 11.19M | 22.52M | 6.58M | 10.52M |
| Change in Working Capital | (48.19M) | (60.38M) | 4.97M | (5.79M) | (8.06M) |
| Accounts Receivables | (2.69M) | 3.32M | 907K | 7.98M | (243K) |
| Inventory | 211K | 920K | 0 | 0 | 0 |
| Accounts Payables | (219K) | 92K | 2.83M | (2.93M) | 1.07M |
| Other Working Capital | (45.5M) | (64.71M) | 1.23M | (10.84M) | (8.89M) |
| Other Non-Cash Items | 2.13M | 2.29M | 159.21M | 51.52M | 60.14M |
| Operating Cash Flow | (60.38M) | (31.63M) | (51.16M) | (23.67M) | (73.94M) |
| Capital Expenditures | (1.09M) | (1.2M) | (206K) | (9.09M) | (5.45M) |
| Acquisitions (Net) | 0 | 0 | 6.56M | 351K | 0 |
| Purchases of Investments | (32.46M) | (33.5M) | 0 | 0 | 0 |
| Sales of Investments | 16.4M | 19.7M | 28.25M | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (17.14M) | (15M) | 34.61M | (8.74M) | (5.45M) |
| Debt Repayment | 0 | 0 | (27.46M) | 0 | 0 |
| Common Stock Issued | 51.96M | 38.98M | 0 | 124.44M | (301K) |
| Common Stock Repurchased | 0 | 0 | (6.17M) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 939K | 235K | 231K | 3.99M | (7.75M) |
| Financing Cash Flow | 52.9M | 39.22M | (13.15M) | 168.43M | (8.06M) |
| Effect of Forex Changes | (3K) | 20K | (53K) | (21K) | 45K |
| Net Change in Cash | (24.63M) | (7.4M) | (29.75M) | 135.99M | (87.41M) |
| Free Cash Flow | (61.47M) | (32.83M) | (51.37M) | (32.77M) | (79.4M) |
Cartesian Therapeutics, Inc.
NASDAQ:RNAC
Intrinsic Alpha fair value
Locked
Current Price
$6.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.